Indoor way-finder launched at Chelsea & Westminster Hospital NHS Foundation Trust

BuzzStreets and Chelsea & Westminster Hospital NHS Foundation Trust are launching a unique indoor way-finder for hospitals to help patients and their families navigate their way around more easily, reduce staff time spent giving directions, help ensure patients arrive on time for appointments, reduce stress, and minimise traffic in the corridors. Research has shown that…

EC approves PONVORY (ponesimod)

European Commission approves PONVORYTM ▼ (ponesimod), a Once Daily, Oral Therapy for the Treatment of Adults with Relapsing Forms of Multiple Sclerosis with Active Disease Defined by Clinical or Imaging Features The pivotal Phase 3 OPTIMUM trial showed treatment with ponesimod led to a 30.5 percent reduction in annual relapse rate (p<0.001) vs. treatment with teriflunomide, an…

PhD Opportunity: Computer games to support arm rehabilitation after stroke 

Background Stroke is one of the most common causes of disability across the world. Up to 80% of acute stroke patients experience loss of arm function, which affects quality of life. Arm impairment often persists after rehabilitation has ceased. Recovery may be optimised by intensive functional training, but this can be difficult after stroke e.g….

Find ACNR articles in EuropePMC/PubMed

We have recently added the article Hallucinations in Parkinson’s disease to EuropePMC on behalf of authors Rimona Weil and Suzanne Reeves.  Is your work supported by funders on this list?  If you write about your work for ACNR, we can add your article to EuropePMC with no charges for you or your institution. Contact the…

ACNR joins Crossref

We’re delighted to announce that ACNR has joined Crossref, and will be allocating DOI’s to new articles. We have also started adding DOI’s to existing articles, but as we have been publishing for almost 20 years we have quite a lot of content to work through! If you have published an article with us in…

New real-world data for ONGENTYS®▼ (opicapone) released at the MDS

New data presented 12-16 September at the MDS 2020 Virtual Congress further support the efficacy and tolerability of ONGENTYS® (opicapone) observed in pivotal Phase III studies. Opicapone is a once-daily catechol-O-methyltransferase (COMT) inhibitor, approved for the treatment of end-of-dose motor fluctuations in adult PD patients taking levodopa. Data from OPTIPARK study demonstrated consistently low incidence of treatment-related adverse events in clinical practice from the…

Funding boost for AI-based epilepsy monitoring

University spinout company Neuronostics has received funding to develop its BioEP platform, an AI-based system for faster, more accurate diagnosis of epilepsy and to monitor response to treatment with anti-epileptic drugs (AEDs).  BioEP works by creating mathematical models of the brain using short segments of electroencephalogram (EEG) recordings. Computer simulations rapidly reveal the ease with…

SPRAVATO®▼ (esketamine) nasal spray for treatment-resistant major depressive disorder recommended in Scotland – but not England

The Janssen Pharmaceutical Companies of Johnson & Johnson are delighted that the Scottish Medicines Consortium (SMC) accepted SPRAVATO®▼ (esketamine) nasal spray (7th September 2020) for use within NHS Scotland in combination with a selective serotonin reuptake inhibitor (SSRI) or serotonin-norepinephrine reuptake inhibitor (SNRI), for adults with treatment-resistant Major Depressive Disorder (TRD), who have not responded…